Efficacy News and Research

RSS

Phase 3 trial results show that new testosterone nasal gel is effective and practical

A new testosterone nasal gel raises men's low testosterone levels to normal, with few side effects, according to the results of a phase 3 clinical trial to be presented Saturday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).

8 Mar 2015

Liraglutide may help obese adults achieve weight loss

Obesity guidelines recommend an initial weight loss goal of 5 to 10% of start weight to improve health. A recent study found that patients who received liraglutide 3.0 mg, combined with fewer calories and more physical activity, were more than twice as likely to achieve at least that level of weight loss, compared to patients on placebo who made similar lifestyle changes.

7 Mar 2015

TSO3's new STERIZONE VP4 Sterilizer to be showcased at AORN Surgical Conference & Expo 2015

TSO3 Inc. an innovator in sterilization technology for medical devices in healthcare settings, announced today that it will showcase its new STERIZONE VP4 Sterilizer at the AORN Surgical Conference & Expo 2015, held in Denver, Colorado from March 7 to 11, 2015.

6 Mar 2015

Researchers study safety, effectiveness of experimental Ebola vaccine following high-risk exposure

A physician who received an experimental Ebola vaccine after experiencing a needle stick while working in an Ebola treatment unit in Sierra Leone did not develop Ebola virus infection, and there was strong Ebola-specific immune responses after the vaccination, although because of its limited use to date, the effectiveness and safety of the vaccine is not certain, according to a study appearing in JAMA.

6 Mar 2015

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Novogen today announces that Professor Gil Mor MD PhD from Yale Medical School will be presenting pre-clinical data on the lead candidate product, Cantrixil, at two upcoming conferences.

6 Mar 2015

Plant molecule helps female mice combat weight gain

A molecule found in some plants can combat weight gain induced by a high-fat diet, but only in female mice, not males. 7,8-dihydroxyflavone (7,8-DHF) is thought to mimic the effects of a growth factor induced by exercise.

6 Mar 2015

Key 'energy producing' protein plays a critical role in a good immune system

A good immune system relies on a key 'energy producing' protein in immune cells to develop immunity to vaccines and disease, an international team of scientists has found.

6 Mar 2015

Asterias begins enrollment for AST-OPC1 Phase 1/2a trial to treat complete cervical spinal cord injury

Asterias Biotherapeutics, Inc., a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one of the nation's top rehabilitation hospitals for spinal cord injury and brain injury, has commenced enrollment for the Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI).

5 Mar 2015

VolitionRx begins pilot study to assess feasibility of NuQ assays in detecting prostate cancer

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has initiated a pilot study to assess the feasibility of VolitionRx's proprietary NuQ assays in detecting prostate cancer.

5 Mar 2015

Phase III trial to test VSV-EBOV vaccine for preventing Ebola to be launched in Guinea

Based on promising data from initial clinical trials in late 2014, WHO with the Health Ministry of Guinea, Médecins Sans Frontières, Epicentre and The Norwegian Institute of Public Health, will launch a Phase III trial in Guinea on 7 March to test the VSV-EBOV vaccine for efficacy and effectiveness to prevent Ebola.

5 Mar 2015

Scientists develop nanocarriers for lung cancer treatment

Nanoparticles can function as carriers for medicines to combat lung cancer: Working in a joint project at the NIM (Nanosystems Initiative Munich) Excellence Cluster, scientists from the Helmholtz Zentrum München and the Ludwig-Maximilians-Universität in Munich have developed nanocarriers that site-selectively release medicines/drugs at the tumor site in human and mouse lungs.

5 Mar 2015

electroCore’s gammaCore device effective in helping patients prevent, treat cluster headache

A twelve-month open-label study in the March issue of the journal Neurology, reports that electroCore’s non-invasive Vagus Nerve stimulation (nVNS) device, gammaCore, is practical and effective as an acute and preventative treatment in cluster headache. Seventy-nine percent of patients who completed the trial (15 out of 19) reported an overall improvement in their condition.

5 Mar 2015

GeneSight test better predicts antidepressant outcomes for patients with depression

The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the individual genes that comprise the test, according to a peer-reviewed analysis by investigators from the Mayo Clinic and Assurex Health, and published online by The Pharmacogenomics Journal.

5 Mar 2015

Bayer announces FDA acceptance of BAY 81-8973 BLA for treatment of hemophilia A

Bayer HealthCare today announced that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for BAY 81-8973, a recombinant Factor VIII compound. Bayer is seeking FDA approval of the investigational compound, proposed trade name Kovaltry, for the treatment of hemophilia A in children and adults.

4 Mar 2015

Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from its Phase 1 clinical program demonstrating that its lead product candidate, SYM-1219, was safe and well tolerated and had predictable pharmacokinetics (PK), and that contraceptive efficacy for birth control pills would not be altered by SYM-1219 administration.

4 Mar 2015

Resverlogix, Emerald Logic complete collaborative research program

Resverlogix Corp. today announced that it has completed a collaborative research program with Emerald Logic, a leader in quantitative analytics. Using Fast Collective Evolution Technology (FACET), Emerald Logic analyzed Resverlogix's complete clinical dataset including all measurements obtained from each of 798 patients who participated in the Company's Phase 2 clinical trials ASSERT, SUSTAIN and ASSURE.

4 Mar 2015

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Pharma Two B announced today that enrollment has been completed in the company's Phase IIb study of P2B001 for the treatment of early stage Parkinson's disease. One hundred and forty-nine patients enrolled in the study conducted at 29 clinical sites throughout the US and Israel.

4 Mar 2015

Study demonstrates that activation of cannabinoid CB2 receptors suppresses chronic pain

Medical marijuana is proliferating across the country due to the ability of cannabis ingestion to treat important clinical problems such as chronic pain. However, negative side effects and the development of tolerance limit the widespread therapeutic use of Δ9-tetrahydrocannabinol (Δ9-THC), the major psychoactive ingredient in cannabis.

4 Mar 2015

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

SARAH, a large French study of patients with advanced, inoperable primary liver cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding its 400-patient target, according to its principal investigator, Professor Valérie Vilgrain MD, PhD, Department of Radiology, Beaujon Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) and Université Paris Diderot, Sorbonne Paris Cité, France.

4 Mar 2015

Efficacy News and Research

Phase 3 trial results show that new testosterone nasal gel is effective and practical

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Liraglutide may help obese adults achieve weight loss

TSO3's new STERIZONE VP4 Sterilizer to be showcased at AORN Surgical Conference & Expo 2015

Researchers study safety, effectiveness of experimental Ebola vaccine following high-risk exposure

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Plant molecule helps female mice combat weight gain

Key 'energy producing' protein plays a critical role in a good immune system

Asterias begins enrollment for AST-OPC1 Phase 1/2a trial to treat complete cervical spinal cord injury

VolitionRx begins pilot study to assess feasibility of NuQ assays in detecting prostate cancer

Phase III trial to test VSV-EBOV vaccine for preventing Ebola to be launched in Guinea

Scientists develop nanocarriers for lung cancer treatment

electroCore’s gammaCore device effective in helping patients prevent, treat cluster headache

GeneSight test better predicts antidepressant outcomes for patients with depression

Bayer announces FDA acceptance of BAY 81-8973 BLA for treatment of hemophilia A

Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Resverlogix, Emerald Logic complete collaborative research program

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Study demonstrates that activation of cannabinoid CB2 receptors suppresses chronic pain

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News